India’s Serum Institute and Novavax Inc whose COVID-19 vaccine candidate showed promising results in the initial clinical trials have signed an exclusive supply and license agreement for the production of the COVID-19 vaccine in India.
Apart from the exclusive production and development license of the vaccine in India, Serum institute has also struck a deal to get non-exclusive rights to produce the drug in other developing nations as well, reported Financial Express (FE) quoting the news agency Reuters.
The deal, signed on July 30, will last til
l the time COVID-19 pandemic gets over, the report added.
More details about the vaccine and its trial:
- Volunteers who had been administered the vaccine developed twice the amount of antibodies compared to patients who had recovered from the disease.
- The results had been achieved after two small doses of the vaccine were injected into the volunteers who participated in its clinical trials.
- A total of 106 volunteers between the age of 18 and 59 had been enrolled in the clinical trial conducted by the company in May.
- The vaccine is one of the few promising candidates that were directly funded by the US government.
- An amount of $1.6 billion aid had also been provided to the company by the Donald Trump administration to take care of its production and clinical trial expenses.